With Woodcock’s Retirement, US FDA Loses A Renaissance Woman
Executive Summary
FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues say.
You may also be interested in...
US FDA Regulatory Affairs Reorg To Include Inspectors Trained In Real-World Evidence, Califf Says
The US FDA Commissioner acknowledged that the inspectorate has not been prepared for RWE, but as part of the revamp, a dedicated team will encourage its use “when it’s appropriate.”
‘I’m Still Here’: Janet Woodcock’s Swan Song At US FDA Looking Like A Longer-Term Job
Janet Woodcock’s imminent departure from the agency has been predicted often during her tenure. Her latest project may keep her there longer than even she thought possible.
Woodcock Focusing On Food Issues, Rather Than Drugs, As US FDA’s Principal Deputy Commissioner
Commissioner Robert Califf wants Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.